Modulation of the Innate Immune System by Fisetin for the Treatment of AD
Award amount
$149,997Program and phase
SBIR · Phase IAward year
2013Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- COLLABORATIVE DRUG DISCOVERY, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- KC1DAXHM8424
- Solicitation number
- PAR09-220
- Topic code
- NCATS
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A Robust, Secure Framework to Effortlessly Bind Distributed Databases and Analysis Tools into Tightly Integrated Translational Drug Discovery Computational Platforms
- Intelligent Chemical Structure Browser for Drug Discovery and Optimization
- Novel deep learning strategy to better predict pharmacological properties of candidate drugs and focus discovery efforts
- Digital representation of chemical mixtures to aid drug discovery and formulation
- Intelligent Chemical Structure Browser for Drug Discovery and Optimization
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- A Novel Multi-Lineage Human Intestinal Organoid Screening Platform for Drug Discovery and Preclinical Testing
- A Novel Approach to Eliminate Length Impurities for High-Quality mRNA Production
- Development of CIL-0X: A Platform to Enhance Delivery of Inhaled RNA Therapeutics to Lung Cells
- Tethosomes: a non-viral DNA platform for durable expression of therapeutic transgenes in specific target cells
- Long-read sequencing-based diagnosis for complex genomic and DNA methylation changes
Research funding history
17 SBIR/STTR records share this UEI (2010–2022). Reported award amounts total $14,412,575. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services